Loading…
Swiss maker of hip and knee joint replacement implants and minimally-invasive surgical instrumentation.
Swiss maker of hip and knee joint replacement implants and minimally-invasive surgical instrumentation.
Sells implants and the instrument sets used to place them to hospitals, directly in some markets and through distributors elsewhere, and trains surgeons at its own institute so they adopt its techniques. Hips and knees carry the business. The Siccardi family, which founded it, remains the controlling shareholder.
In one line: A smaller Swiss Stryker/Zimmer Biomet for joint implants.
Moat: narrow (brand, switching costs, distribution). Surgeon training and technique loyalty (AMIS) create switching costs versus larger rivals.
Headquarters: Castel San Pietro, Switzerland · Founded: 1999 · Employees: 2,165
Size Medacta (MOVE.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $2.61B, the 83rd largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 106.40 on 6 Nov 2026.
Performance Over six months the shares fell 21.3%, against +5.1% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 7.5% over the last twelve months (peer median +7.7%); the operating margin is 14.9% (peer median 7.3%).
Valuation It trades at 24.3× forward earnings against a peer median of 31.5× (7th cheapest of 19).
Capital Return on invested capital runs 5.7 points above its cost of capital (5.4% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 655M | CHF 641M | CHF 563M | CHF 496M | CHF 439M |
| Revenue growth | — | +14% | +13% | +13% | — |
| Gross profit | CHF 429M | CHF 411M | CHF 362M | CHF 320M | CHF 289M |
| EBITDA | CHF 174M | CHF 177M | CHF 150M | CHF 131M | CHF 121M |
| Net income | CHF 71.5M | CHF 89.5M | CHF 69.4M | CHF 46.0M | CHF 46.4M |
| Free cash flow | -CHF 1.60M | CHF 27.8M | CHF 17.0M | CHF 3.78M | CHF 10.4M |
| Capital expenditure | CHF 149M | CHF 134M | CHF 99.7M | CHF 79.9M | CHF 71.5M |
| Total debt | n/a | CHF 244M | CHF 229M | CHF 189M | CHF 170M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Medacta MOVE.SW | $2.61B | -21% | +8% | 15% | 24.3× | n/a |
| Zimmer Biomet ZBH | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% |
| Stryker SYK | $124B | +14% | +8% | 25% | 20.4× | 10.6% |
| Smith & Nephew SN..L | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOVE.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +7.9% | 6th lowest of 21 |
| 6-month return | -21.3% | +5.1% | 5th lowest of 21 |
| Distance from 52-week high | -40.0% | -21.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +7.5% | +7.7% | 10th lowest of 20 |
| Operating margin | 14.9% | 7.3% | 8th highest of 20 |
| Forward P/E | 24.3× | 31.5× | 7th cheapest of 19 |
| ROIC minus cost of capital | +5.7 pp | -0.4 pp | 7th highest of 20 |
| EV / EBITDA | 13.7× | 26.9× | 3rd cheapest of 10 |
| Net debt / EBITDA | 1.5× | 2.6× | 6th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medacta MOVE.SW | Switzerland | $2.61B | -21% | +8% | 15% | 24.3× | n/a | n/a |
| Neogen NEOG | United States | $2.57B | +30% | 0% | 0% | 34.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% | +10.4% |
| EBOS EBO.AX | Australia | $2.52B | +1% | +3% | 3% | 15.2× | 4.3% | +6.8% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.46B | +3% | +6% | 18% | 29.0× | 12.8% | +19.2% |
| Jafron Biomedical 300529.SZ | China | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% | +0.6% |
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 34.0× | n/a | n/a |
| Elekta EKTA-B.ST | Sweden | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% | +4.0% |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.27B | -27% | +8% | 29% | 22.1× | -1.6% | +14.1% |
| Metall Zug METN.SW | Switzerland | $2.25B | +19% | 0% | -10% | 139.2× | n/a | n/a |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |